Nadira Duraković, Zinaida Perić, Sandra Bašić Kinda, Lana Desnica, Dino Dujmović, Ivo Radman Livaja, Ranka Serventi Seiwerth, Igor Aurer, Radovan Vrhovac
{"title":"The Impact of Achieving Complete Remission Prior to Allogeneic Stem Cell Transplantation on Progression-Free Survival in Hodgkin Lymphoma.","authors":"Nadira Duraković, Zinaida Perić, Sandra Bašić Kinda, Lana Desnica, Dino Dujmović, Ivo Radman Livaja, Ranka Serventi Seiwerth, Igor Aurer, Radovan Vrhovac","doi":"10.2991/chi.k.210704.002","DOIUrl":null,"url":null,"abstract":"Allogeneic hematopoietic stem cell transplantation (alloHSCT) is a potential curative option for patients suffering from relapsed/ refractory (r/r) Hodgkin lymphoma (HL) after autologous stem cell transplantation (ASCT), offering a survival advantage over standard chemotherapy approaches [1]. However, two recently approved new drug treatments for r/r HL after ASCT [antiCD30 antibody-drug conjugate, brentuximab-vedotin (BV) and immune-checkpoint inhibitors (ICI)], demonstrated long-term disease control, with 38% and 16% of patients achieving complete response (CR), respectively [2]. These results have lately triggered much debate whether patients need to undergo alloHSCT at all after achieving response with BV or ICI [3,4].","PeriodicalId":10368,"journal":{"name":"Clinical Hematology International","volume":"3 3","pages":"116-118"},"PeriodicalIF":0.0000,"publicationDate":"2021-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/08/34/CHI-3-3-116.PMC8486971.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Hematology International","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2991/chi.k.210704.002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/9/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
Allogeneic hematopoietic stem cell transplantation (alloHSCT) is a potential curative option for patients suffering from relapsed/ refractory (r/r) Hodgkin lymphoma (HL) after autologous stem cell transplantation (ASCT), offering a survival advantage over standard chemotherapy approaches [1]. However, two recently approved new drug treatments for r/r HL after ASCT [antiCD30 antibody-drug conjugate, brentuximab-vedotin (BV) and immune-checkpoint inhibitors (ICI)], demonstrated long-term disease control, with 38% and 16% of patients achieving complete response (CR), respectively [2]. These results have lately triggered much debate whether patients need to undergo alloHSCT at all after achieving response with BV or ICI [3,4].
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
